This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the 36-Week topline data from the Phase 2 Study of Silence Therapeutics' zerlasiran in Patients with High Lipoprotein(a)
Ticker(s): SLNWho's the expert?
Institution: Private Practice
- Board-certified clinical lipidologist in private practice located in Scottsdale, Arizona.
- Currently manages 20 patients with elevated levels of lipoprotein(a).
- Currently serves as a Principal Investigator on 12 clinical trials.
Interview GoalThis call will feature a discussion of the current standard of care and the potential of Zerlasiran (SLN360) being developed by Silence Therapeutics for the treatment of high lipoprotein(a). There will also be an analysis of the topline 36-week data from the ongoing phase 2 study of Zerlasiran.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
